These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ceftriaxone in the treatment of serious infections, particularly after surgery. Scully BE; Neu HC Am J Surg; 1984 Oct; 148(4A):35-40. PubMed ID: 6091479 [TBL] [Abstract][Full Text] [Related]
4. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Bradsher RW; Snow RM Am J Med; 1984 Oct; 77(4C):63-7. PubMed ID: 6093522 [TBL] [Abstract][Full Text] [Related]
5. Ceftriaxone for once-a-day therapy of urinary tract infections. Childs SJ; Wells WG; Mirelman S Am J Med; 1984 Oct; 77(4C):73-6. PubMed ID: 6093524 [TBL] [Abstract][Full Text] [Related]
6. Ceftriaxone therapy of meningitis and serious infections. Steele RW Am J Med; 1984 Oct; 77(4C):50-3. PubMed ID: 6093519 [TBL] [Abstract][Full Text] [Related]
7. Rationale for clinical trials evaluating ceftriaxone in the therapy of bacterial meningitis. Scheld WM; Rocha H; Sande MA; Bryan JP Am J Med; 1984 Oct; 77(4C):42-9. PubMed ID: 6093518 [TBL] [Abstract][Full Text] [Related]
8. Clinical and bacteriologic efficacy of ceftriaxone in the United States. McCloskey RV Am J Med; 1984 Oct; 77(4C):97-103. PubMed ID: 6093528 [TBL] [Abstract][Full Text] [Related]
9. [Long-term administration of ceftriaxone (Ro 13-9904) to complicated urinary tract infections]. Oishi K; Kawakita M; Hida S; Higashi Y; Yamauchi T; Yoshida O Hinyokika Kiyo; 1985 Apr; 31(4):711-21. PubMed ID: 4036746 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of ceftriaxone in serious bacterial infections. Epstein JS; Hasselquist SM; Simon GL Antimicrob Agents Chemother; 1982 Mar; 21(3):402-6. PubMed ID: 6285809 [TBL] [Abstract][Full Text] [Related]
11. [Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli]. Naessens A; Pierard D; Roels P; Lauwers S Pathol Biol (Paris); 1983 May; 31(5):362-5. PubMed ID: 6312398 [TBL] [Abstract][Full Text] [Related]
12. [Ceftriaxone, a long-acting cephalosporin. Microbiological, kinetic and clinical study]. Soranzo ML; Capra E; Angela GC; Eandi M; Salassa B; Lollini P; Musso E; Pizzo L; Spezia C; Di Nola F Minerva Med; 1983 Sep; 74(36):2093-102. PubMed ID: 6312379 [TBL] [Abstract][Full Text] [Related]
13. Experience with ciprofloxacin in vitro and in vivo. Giamarellou H; Efstratiou A; Tsagarakis J; Petrikkos G; Daikos GK Arzneimittelforschung; 1984; 34(12):1775-8. PubMed ID: 6442151 [TBL] [Abstract][Full Text] [Related]
14. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Guggenbichler JP; Allerberger FJ; Dierich M Padiatr Padol; 1986; 21(4):335-42. PubMed ID: 3562044 [TBL] [Abstract][Full Text] [Related]
15. [Microbiologic and clinical significance of cefotiam]. Tauchnitz C; Ezold R; Bauer I; Berger HD; Buhl C; Goedecke A; Morawietz I Z Gesamte Inn Med; 1985 Mar; 40(5):143-8. PubMed ID: 3857792 [TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of ceftriaxone in children]. Terashima I; Uehara S; Toba T; Hayashi T; Hoshi M Jpn J Antibiot; 1984 Nov; 37(11):2021-6. PubMed ID: 6098698 [TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation on ceftriaxone in the field of pediatrics]. Haruta T; Kuroki S; Mayumi M; Matsuo H; Ohkura K; Kobayashi Y Jpn J Antibiot; 1984 Nov; 37(11):2141-51. PubMed ID: 6098707 [TBL] [Abstract][Full Text] [Related]